Related Experiment Video
Updated: Nov 6, 2025

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Autophagic Markers in Chordomas: Immunohistochemical Analysis and Comparison with the Immune Microenvironment of
Georgia Karpathiou1, Maroa Dridi1, Lila Krebs-Drouot2
1Pathology Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.
Abstract:
Chordomas are notably resistant to chemotherapy. One of the cytoprotective mechanisms implicated in chemoresistance is autophagy. There are indirect data that autophagy could be implicated in chordomas, but its presence has not been studied in chordoma tissues. Sixty-one (61) chordomas were immunohistochemically studied for autophagic markers and their expression was compared with the expression in notochords, clinicopathological data, as well as the tumor immune microenvironment. All chordomas strongly and diffusely expressed cytoplasmic p62 (sequestosome 1, SQSTM1/p62), whereas 16 (26.2%) tumors also showed nuclear p62 expression. LC3B (Microtubule-associated protein 1A/1B-light chain 3B) tumor cell expression was found in 44 (72.1%) tumors. Autophagy-related 16‑like 1 (ATG16L1) was also expressed by most tumors. All tumors expressed mannose-6-phosphate/insulin-like growth factor 2 receptor (M6PR/IGF2R). LC3B tumor cell expression was negatively associated with tumor size, while no other parameters, such as age, sex, localization, or survival, were associated with the immunohistochemical factors studied. LC3B immune cell expression showed a significant positive association with programmed death-ligand 1 (PD-L1)+ immune cells and with a higher vascular density. ATG16L1 expression was also positively associated with higher vascular density. Notochords (n = 5) showed different immunostaining with a very weak LC3B and M6PR expression, and no p62 expression. In contrast to normal notochords, autophagic factors such as LC3B and ATG16L1 are often present in chordomas, associated with a strong and diffuse expression of p62, suggesting a blocked autophagic flow. Furthermore, PD-L1+ immune cells also express LC3B, suggesting the need for further investigations between autophagy and the immune microenvironment.
Insights
Autophagy markers like LC3B and ATG16L1 are often present in chordoma tumors, unlike normal notochords, suggesting a blocked autophagic flow. Immune cells expressing PD-L1 also show LC3B, indicating a link between autophagy and the tumor immune microenvironment.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Chordomas exhibit chemoresistance, potentially linked to autophagy.
- Autophagy's role in chordomas is not well-understood.
- This study investigates autophagic markers in chordoma tissues.
Purpose of the Study:
- To examine the expression of key autophagy markers (p62, LC3B, ATG16L1, M6PR/IGF2R) in chordoma tissues.
- To compare autophagic marker expression in chordomas versus normal notochords.
- To correlate autophagic marker expression with clinicopathological data and the tumor immune microenvironment.
Main Methods:
- Immunohistochemical analysis of 61 chordoma tissues and 5 notochord samples.
- Assessment of p62, LC3B, ATG16L1, and M6PR/IGF2R expression.
- Correlation analysis with clinicopathological features and immune markers (PD-L1).
Main Results:
- Chordomas showed strong p62 expression and frequent LC3B and ATG16L1 expression, unlike notochords.
- LC3B expression correlated negatively with tumor size.
- Immune cell LC3B expression was associated with PD-L1+ cells and higher vascular density.
Conclusions:
- Chordomas frequently exhibit signs of blocked autophagy (high p62, present LC3B/ATG16L1) compared to notochords.
- Autophagy markers correlate with specific tumor microenvironment features, including PD-L1 expression.
- Further research is needed to explore the interplay between autophagy and the immune microenvironment in chordomas.
More Related Videos
11:00Visualization, Quantification, and Mapping of Immune Cell Populations in the Tumor Microenvironment
Published on: March 25, 2020
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024